Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.

Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Moderna's Q4 earnings due Feb 14: analysts predict revenue decline & $2.73 loss. Explore vaccine demand, pipeline prospects, and stock outlook.

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger ...

Moderna is a victim of its own success ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

In contrast to shares of AbbVie and Gilead Sciences, which have been strong performers to kick off 2025, Moderna (NASDAQ: MRNA) stands out as a turnaround opportunity. The company, recognized for ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Healthcare company Moderna is an example of a business that I see as blowing a huge opportunity to diversify in recent years. It generated billions in revenue from its successful COVID vaccine ...

Stocks recently featured in the blog include: Amgen AMGN, CRISPR Therapeutics CRSP, Moderna MRNA, Sarepta Therapeutics SRPT and Vertex Pharmaceuticals VRTX. Here are highlights from Wednesday’s ...